Today starts ASCO 2017 The Annual Meeting in Chicago, the biggest conference on oncology. It brings together oncology professionals from around the world to discuss state-of-the-art treatment modalities, new therapies, and ongoing controversies in the field. Chronix Biomedical is present and invites to its booth in the Exhibition Hall since Saturday.
This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy. We invite all interested doctors to visit us at a Booth #5147 and meet the experts that were involved in the study. Chronix is planning a series of further clinical trials focused on specific cancers. The company is actively recruiting clinical practices to join in the clinical trials of this important blood test that monitors treatment outcomes. In an interview for Clinical Oncologist Daily Prof. Ekkehard Schütz, M.D, Ph.D, FACD. Chief Medical and Technology Officer of Chronix Biomedical said – “We believe meetings at our booth at ASCO can be a great opportunity to join Chronix in our project #TheTurningPointInCancerFight”.